Media stories about LivaNova (NASDAQ:LIVN) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. LivaNova earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.4716959579726 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
LIVN has been the subject of a number of research reports. Jefferies Group initiated coverage on LivaNova in a research report on Friday, September 8th. They set a “buy” rating and a $76.00 target price for the company. Needham & Company LLC upgraded LivaNova from a “hold” rating to a “buy” rating and set a $83.00 target price for the company in a research report on Friday, September 15th. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Piper Jaffray Companies reiterated an “overweight” rating and set a $75.00 target price on shares of LivaNova in a research report on Tuesday, September 12th. Finally, WBB Securities downgraded LivaNova from a “hold” rating to a “sell” rating and set a $50.00 target price for the company. in a research report on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $79.71.
LivaNova (LIVN) traded up $0.19 during mid-day trading on Thursday, reaching $83.92. The company’s stock had a trading volume of 574,349 shares, compared to its average volume of 392,367. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.42 and a current ratio of 2.03. LivaNova has a twelve month low of $44.58 and a twelve month high of $88.56. The stock has a market capitalization of $4,040.00 and a price-to-earnings ratio of 24.10.
LivaNova (NASDAQ:LIVN) last released its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.17. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The business had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. During the same quarter last year, the firm posted $0.78 earnings per share. The business’s revenue was up 4.9% compared to the same quarter last year. equities research analysts forecast that LivaNova will post 3.33 earnings per share for the current fiscal year.
In other news, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $74.58, for a total value of $74,580.00. The disclosure for this sale can be found here. Insiders have sold a total of 6,830 shares of company stock worth $557,100 in the last three months. Corporate insiders own 0.28% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/07/livanova-livn-receiving-somewhat-positive-media-coverage-report-shows.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.